Literature DB >> 24303466

Tumour induced osteomalacia due to a sinonasal hemangiopericytoma: A case report.

Sophie A Jamal1, Brendan C Dickson, Ina Radziunas.   

Abstract

Tumour induced osteomalacia (TIO) is a rare and often unrecognized cause of hypophosphatemia. We report on a case of TIO due to a hemangiopericytoma originating from the left nasal sinus. The patient was a 55-year-old male with a 3-year history of left hip pain and an undisplaced left hip fracture. Biochemical testing demonstrated low levels of serum phosphate and serum 1,25-dihydroxyvitamin D, and an elevated level of fibroblast growth factor 23. Octreotide scanning demonstrated uptake in the left nasal sinus area and a computed tomography scan revealed a left nasal sinus mass. The patient underwent surgical resection of the mass and histology was consistent with a sinonasal hemangiopericytoma. His serum phosphate levels normalized almost immediately after surgery and he had complete resolution of hip pain. Our case highlights the importance of considering TIO when assessing patients with low serum phosphate.

Entities:  

Keywords:  Fibroblast growth factor 23; Osteomalacia; Phosphate; Tumour

Year:  2013        PMID: 24303466      PMCID: PMC3845926          DOI: 10.12998/wjcc.v1.i1.59

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  19 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  M K Drezner
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

2.  [Rickets following bone tumor].

Authors:  A PRADER; R ILLIG; E UEHLINGER; G STALDER
Journal:  Helv Paediatr Acta       Date:  1959-12

3.  Tumor-induced osteomalacia.

Authors:  Suzanne M Jan de Beur
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

Review 4.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

5.  Oncogenic osteomalacia: lesion detection by MR skeletal survey.

Authors:  N A Avila; M Skarulis; D M Rubino; J L Doppman
Journal:  AJR Am J Roentgenol       Date:  1996-08       Impact factor: 3.959

6.  Localisation of mesenchymal tumours by somatostatin receptor imaging.

Authors:  Suzanne M Jan de Beur; Elizabeth A Streeten; A Cahid Civelek; Edward F McCarthy; Liliana Uribe; Stephen J Marx; Olufunmilayo Onobrakpeya; Lawrence G Raisz; Nelson B Watts; Michael Sharon; Michael A Levine
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

7.  Distinctive tumours of bone and soft tissue causing acquired vitamin-D-resistant osteomalacia.

Authors:  D J Evans; J G Azzopardi
Journal:  Lancet       Date:  1972-02-12       Impact factor: 79.321

8.  Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case.

Authors:  J L Dupond; H Mahammedi; D Prié; F Collin; H Gil; O Blagosklonov; B Ricbourg; N Meaux-Ruault; B Kantelip
Journal:  Bone       Date:  2005-03       Impact factor: 4.398

9.  Case records of the Massachusetts General Hospital. Case 33-2011. A 56-year-old man with hypophosphatemia.

Authors:  Clemens Bergwitz; Michael T Collins; Ravi S Kamath; Andrew E Rosenberg
Journal:  N Engl J Med       Date:  2011-10-27       Impact factor: 91.245

10.  Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia.

Authors:  Yasuhiro Takeuchi; Hisanori Suzuki; Sayoko Ogura; Rie Imai; Yuji Yamazaki; Takeyoshi Yamashita; Yoshinari Miyamoto; Hiroshi Okazaki; Kozo Nakamura; Kazuhiko Nakahara; Seiji Fukumoto; Toshiro Fujita
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

View more
  1 in total

1.  Sinonasal hemangiopericytoma caused hypophosphatemic osteomalacia: A case report.

Authors:  Jing Li; Yuanyuan Huang; Fuzhou Yang; Qi Zhang; Decai Chen; Qin Wang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.